<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556917</url>
  </required_header>
  <id_info>
    <org_study_id>2.264.773</org_study_id>
    <nct_id>NCT03556917</nct_id>
  </id_info>
  <brief_title>The Effects of Iontophoresis in Women With Gynoid Hidrolipodystrophy.</brief_title>
  <official_title>The Effects of Iontophoresis in Women With Gynoid Hidrolipodystrophy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Norte do Paraná</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Norte do Paraná</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Gynoid hydrolipodystrophy (HLDG) or cellulitis is a subcutaneous tissue
      disorder, with several strategies for its treatment, such as caffeine and iontophoresis.
      Objective: To evaluate the effects of caffeine-associated iontophoresis for the treatment of
      HLDG. Methods: In a longitudinal study, participants will be evaluated for: photographic
      documentation, ultrasound imaging, thermography and quality of life questionnaire. If
      included, they will be separated into 3 randomized groups (n = 30). G1: use of base gel (n =
      10); G2: use of iontophoresis and gel with caffeine (n = 10) and G3: use of iontophoresis
      alone (n = 10). The groups will be treated with 10 sessions, 2 times per week. After that
      they will be reevaluated. Statistical analysis: The software used will be the SPSS
      StatisticalPackage (IBM SPSS Statistics, Chicago, IL, USA). The data distribution will be
      analyzed by the Shapiro-Wilk test. In case of normal distribution, the data will be described
      as mean ± standard deviation; otherwise, as median [interquartile range 25-75%]. For
      comparison of the data, we will use ANOVA and for comparison of means the Tukey test and case
      not normal distribution, krulskal-Wallis test and the Dunns test. The level of statistical
      significance adopted will be P &lt;0.05. Expected contributions: It is expected that
      investigators can contribute to the treatment of patients with HLDG and analyze the effects
      of iontophoresis with caffeine, both in clinical and scientific practice, providing a method
      that is valid and reliable for this purpose; multidisciplinary training of highly qualified
      human resources and the strengthening and consolidation of a research team.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2018</start_date>
  <completion_date type="Actual">April 4, 2019</completion_date>
  <primary_completion_date type="Actual">March 17, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>It is a longitudinal and randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>thickness</measure>
    <time_frame>through study completion, an average of 1 year.</time_frame>
    <description>change from baseline subcutaneous adipose tissue thickness at after 10 sessions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>temperature</measure>
    <time_frame>through study completion, an average of 1 year.</time_frame>
    <description>change from baseline superficial temperature of the gluteous skin at after 10 sessions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>score quality of life</measure>
    <time_frame>through study completion, an average of 1 year.</time_frame>
    <description>change from baseline quality of life impact in patients with cellulits at after 10 sessions</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Caffeine</condition>
  <condition>Cellulitis</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>topical gel base + caffeine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iontophoresis + caffeine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iontophoresis</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>iontophoresis + caffeine</intervention_name>
    <description>we will use cafeislaine c (caffeine) +galvanic current</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with mild to moderate cellulite diagnosis will be included, according to the
             validated Photonumeric scale of cellulite severity

          -  Body mass index less than 30 (kg / m2)

        Exclusion Criteria:

          -  Individuals who have a deregulated menstrual cycle who are pregnant;

          -  Breastfeeding or using some hormone;

          -  Antibiotic medication including steroids over 1 month of treatment of skin diseases;
             •Sensitivity or hypersensitivity of the skin;

          -  Use of the same or similar cosmetics or remedies on the glutes within 1 month;

          -  Surgical procedure (liposuction and skin treatments) in the region to be treated or
             planning some procedure within the study period;

          -  Chronic debilitating diseases such as asthma, diabetes or hypertension;

          -  Atopic dermatitis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo A Andraus</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Norte do Paraná</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rodrigo Antonio Carvalho Andraus</name>
      <address>
        <city>Londrina</city>
        <state>Paraná</state>
        <zip>86.041-140</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Hexsel DM, Dal'forno T, Hexsel CL. A validated photonumeric cellulite severity scale. J Eur Acad Dermatol Venereol. 2009 May;23(5):523-8. doi: 10.1111/j.1468-3083.2009.03101.x. Epub 2009 Feb 13.</citation>
    <PMID>19220646</PMID>
  </results_reference>
  <results_reference>
    <citation>Yoo MA, Seo YK, Ryu JH, Back JH, Koh JS. A validation study to find highly correlated parameters with visual assessment for clinical evaluation of cosmetic anti-cellulite products. Skin Res Technol. 2014 May;20(2):200-7. doi: 10.1111/srt.12106. Epub 2013 Sep 7.</citation>
    <PMID>24010809</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Norte do Paraná</investigator_affiliation>
    <investigator_full_name>Alana Roberta Quessada</investigator_full_name>
    <investigator_title>Master student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>http://www.unopar.com.br/</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

